drugset / Trial / NCT05787587
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Timeline
- Start
- 2023-04-18
- Primary completion
- 2026-10
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IDE161 | Unknown | — | Oral |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |